

Attorney Docket No. VNTS-001/001WO 337166-2015**ASSIGNMENT**

Stéphane DORICH, residing at 124 avenue Pendennis, Pointe-Claire, QC H9R 1H6, CANADA; Jason BURCH, residing at 110 Boulevard Saint-Jean, Pointe-Claire, QC H9S 4Z1, CANADA; Miguel ST-ONGE, residing at 1173 rue des Mesanges, Saint-Lazare, QC J7T 2L5, CANADA; Amandine CHEFSON, residing at 6868 rue Jogues, Montreal, QC H4E 2W8, CANADA; Alexandre CÔTÉ, residing at 753 Boul. Union, Laval, QC H7X 1X7, CANADA; Ramsay BEVERIDGE, residing at 73 Ave. Summerhill, Pointe-Claire, QC H9R 2L3, CANADA; and Stéphane CIBLAT, residing at 1260 rue Pauline-Julien, Montreal, QC H2J 0A2, CANADA (each referred to as "Assignor") have made an invention(s) (the "Invention(s)") set forth in an application for patent entitled PYRIDAZINE COMPOUNDS FOR INHIBITING NLRP3, and which is a:

- (1) ☐ provisional application
 (a) ☐ to be filed herewith; or
 (b) ☐ bearing Application No. , and filed on ;
- (2) ☒ Taiwan application
 (a) ☐ to be filed herewith; or
 (b) ☒ bearing Application No. 111113264, and filed on April 7, 2022;
 (c) ☒ bearing Application No. 111140830, and filed on October 27, 2022
 and/or
- (3) ☒ PCT application
 (a) ☒ bearing Application No. PCT/US2022/023893, and filed on April 7, 2022.
 and/or
- (4) ☐ attached hereto.

wherein the above application(s) claim(s) priority to:

Country	Application No.	Application filing date
United States	17/528,928	November 17, 2021
United States	63/171,932	April 7, 2021

WHEREAS, Ventus Therapeutics, Inc., a corporation having its principal place of business at 7150 Frederick-Banting, Montreal, QC H4S 2A1, CANADA (the "Assignee"), its successors, legal representatives and assigns, is desirous of acquiring the Assignors' entire right, title, and interest in: the Invention(s); the application(s) for patent and/or registered design identified above; the right to file applications for patent and/or registered design of the United States or other countries on the Invention(s); any application(s) for patent and/or registered design of the United States or other countries claiming priority to, and/or the benefit of, these applications; any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of these application(s); and any and all patent(s) and/or registered design(s) of the United States or other countries that may be granted therefor or thereon.

NOW, THEREFORE, for good and sufficient consideration, the receipt of which is hereby acknowledged, and to the extent that an Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if an Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of said prior agreement, each Assignor has sold, assigned, transferred, and set over, and by these presents does sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns, the Assignor's entire right, title, and interest in:

- (a) the Invention(s);
- (b) the application(s) for patent identified above;
- (c) the right to file applications for patent and/or registered design of the United States or other countries on the Invention(s), including all rights under the Hague Convention, the Paris Convention for the Protection of Industrial Property, and under the Patent Cooperation Treaty, and all rights of claiming priority in any country of the world;
- (d) any application(s) for patent and/or registered design of the United States or other countries claiming the Invention(s);
- (e) any application(s) for patent and/or registered design of the United States or other countries claiming priority to, and/or the benefit of, at least one of the application(s) for patent identified above or any application(s) for patent and/or registered design claiming the Invention(s), including any priority application(s), substitute application(s), division(s), continuation(s), and continuation(s)-in-part;
- (f) any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of any application for patent and/or registered design identified in the preceding paragraphs (b)-(e) and of any and all patent(s) and/or registered design(s) granted based thereon in the United States and in all other countries; and

(g) any patent(s) and/or registered design(s) of the United States or other countries that may be granted for or on any application for patent and/or registered design identified in the preceding paragraphs (b)-(e), including any reissue(s), reexamination(s), revival(s), renewal(s) and extension(s) of said patent(s) and/or registered design(s).

The above-granted rights, titles, and interests are to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, as fully and entirely as the same would have been held and enjoyed by the Assignor had this sale and assignment not been made.

Each Assignor hereby represents to the Assignee, its successors, legal representatives, and assigns, that, at the time of execution and delivery of these presents, or if applicable, at such time said prior agreement was executed, the Assignor is a lawful owner of an undivided interest in the Assignor's entire right, title, and interest in and to the Invention(s), that the Invention(s) are unencumbered, except, if applicable, by obligation to assign in accordance with said prior agreement, and that the Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth herein, and that Assignor will not make or enter into any assignment, sale, agreement or encumbrance which would conflict with these presents. Each Assignor also hereby represents that, except for said prior agreement, if applicable, the Assignor has not previously sold, transferred, or encumbered any part of Assignor's right, title, and interest in the Invention(s).

Each Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns, that the Assignor will sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done in connection with any and all proceedings for the procurement, maintenance, enforcement and defense of the Invention(s), said application(s), said registered design(s), and said patent(s), including interference and derivation proceedings, and any post-grant proceedings (e.g., opposition proceedings, post-grant reviews, *Inter partes* reviews, supplemental examinations, etc.) without charge to the Assignee, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns.

Each Assignor hereby authorizes and requests the attorneys of COOLEY LLP to insert in the spaces provided above the filing date, the application number, and the attorney docket number of the application(s) identified above when known.

Each Assignor hereby requests the Commissioner of Patents to issue said patents of the United States to the Assignee for the use and behalf of the Assignee, its successors, legal representatives, and assigns.

Assignor(s) and Assignee(s) understand that electronic signatures are acceptable and that, by signing electronically, signatories agree to the use of electronic signatures.

August 1st 2023
Date


Stéphane DORICH

Witness:


Signature

August 1st, 2023
Date

Kelly Pike
Printed Name

Witness:


Signature

August 1st, 2023
Date

Pradhyum Khandelwal
Printed Name

Sept 6, 2023
Date


Jason BURCH

Witness:


Signature

Michele Pichard Ammonche
Printed Name

Sept-6, 2023
Date

Witness:


Signature

Christine Annette
Printed Name

Sept 06, 2023
Date

August 1st 2023
Date

Miguel St-Onge
Miguel ST-ONGE

Witness:

Michele Potlucak Ammonde
Signature

Michele Potlucak Ammonde
Printed Name

August 1st, 2023
Date

Witness:

Silvana Jananji
Signature

SILVANA JANANJI
Printed Name

August 1st, 2023
Date

August 1st 2023
Date


Amandine CHEFSON

Witness:


Signature

Michèle Pokluda Ammonche
Printed Name

August 1st, 2023
Date

Witness:


Signature

Kelly Pike
Printed Name

August 1st, 2023
Date

August 01, 2023
Date

Alexandre Côté
Alexandre CÔTÉ

Witness:

Michèle Pokladá Annoncée
Signature

August 1st, 2023
Date

Michèle Pokladá Annoncée
Printed Name

Witness:

SGAROTO Nicolas
Signature

August 1st, 2023
Date

SGAROTO Nicolas
Printed Name

Aug. 1, 2023

Date

Ramsay Beveridge

Ramsay BEVERIDGE

Witness:

K Pike

Signature

August 1, 2023

Date

Kelly Pike

Printed Name

Witness:

Nichole Pollack Almonche

Signature

August 1st, 2023

Date

Nichole Pollack Almonche

Printed Name

Sept 07, 2023

Date


Stéphane CIBLAT

Witness:

Nadine Fradet

Signature

7-sept-2023

Date

Nadine Fradet

Printed Name

Witness:

Miguel St-Onge

Signature

September 7th 2023

Date

Miguel St-Onge

Printed Name

Attorney Docket No.: VNTS-001/001WO 337166-2015

For and on behalf of ASSIGNEE:

Date: 9/9/2023

By:

DocuSigned by:

Christine Ha

8057FE605FE8409

Name: Christine Ha

Title: Chief Financial Officer

Company: Ventus Therapeutics, Inc.